Literature DB >> 24234752

Association between polymorphism in TRAF1/C5 gene and risk of rheumatoid arthritis: a meta-analysis.

Xingang Zhang, Wei Li, Xinpeng Zhang, Xiaoli Zhang, Li Jiang, Yun Guo, Xiaofei Wang.   

Abstract

Rheumatoid arthritis (RA) is a common chronic inflammatory autoimmune disease. Single nucleotide polymorphisms of tumor necrosis factor-receptor associated factor 1/complement component 5 (TRAF1/C5) gene are suspected to be associated with the risk of RA. This meta-analysis was performed to study the relationship between the polymorphism rs10818488 in TRAF1/C5 gene with RA. We retrieved the relevant articles from PubMed, EMBASE and the China National Knowledge Infrastructure databases. Odd ratios were calculated to assess the association between TRAF1/C5 rs10818488 polymorphism and RA risk. Meta-analyses were performed on the total data set and separately for the major ethnic groups and RF and ACAP status. All analyses were performed using the Stata software. Eight articles were included in the present analysis. Meta-analysis showed a weak association between TRAF1/C5 rs10818488 polymorphism and RA in all subjects (OR = 1.13, 95 % CI = 1.01–1.27, P heterogeneity < 0.001). Stratified analyses indicated that the TRAF1/C5 rs10818488 A allele was significantly associated with RA in Caucasians (OR = 1.29, 95 %CI = 1.14–1.47, P heterogeneity = 0.026), Asians (OR = 0.92, 95 %CI = 0.86–0.99, P heterogeneity = 0.378) and Africans (OR = 1.56, 95 %CI = 1.23–1.98, P heterogeneity = 0.876), also significantly in positive ACPA and positive RF patients versus controls (ORs were 1.20 and 1.25, 95 %CIs were 1.08–1.33 and 1.14–1.37, P values for heterogeneity were 0.215 and 0.133, respectively). Genetic polymorphism rs10818488 in TRAF1/C5 gene might be associated with RA susceptibility.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24234752     DOI: 10.1007/s11033-013-2864-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  24 in total

Review 1.  The immunopathology of joint inflammation in rheumatoid arthritis.

Authors:  N J Zvaifler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

2.  TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies.

Authors:  Jessica A B van Nies; Rute B Marques; Stella Trompet; Zuzana de Jong; Fina A S Kurreeman; Rene E M Toes; J Wouter Jukema; Tom W J Huizinga; Annette H M van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2010-03-05       Impact factor: 5.156

3.  Influence of TRAF1/C5 and STAT4 genes polymorphisms on susceptibility and severity of rheumatoid arthritis in Egyptian population.

Authors:  Rasha H Mohamed; Heba F Pasha; Eman E El-Shahawy
Journal:  Cell Immunol       Date:  2011-12-04       Impact factor: 4.868

4.  TRAF1 is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice.

Authors:  E N Tsitsikov; D Laouini; I F Dunn; T Y Sannikova; L Davidson; F W Alt; R S Geha
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

Review 5.  Tumor necrosis factor receptor-associated factors (TRAFs).

Authors:  J R Bradley; J S Pober
Journal:  Oncogene       Date:  2001-10-01       Impact factor: 9.867

Review 6.  Rheumatoid arthritis: diagnosis and management.

Authors:  Vikas Majithia; Stephen A Geraci
Journal:  Am J Med       Date:  2007-11       Impact factor: 4.965

7.  Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese.

Authors:  K Nishimoto; Y Kochi; K Ikari; K Yamamoto; A Suzuki; K Shimane; Y Nakamura; K Yano; N Iikuni; S Tsukahara; N Kamatani; H Okamoto; H Kaneko; Y Kawaguchi; M Hara; Y Toyama; T Horiuchi; K Tao; K Yasutomo; D Hamada; N Yasui; H Inoue; M Itakura; H Yamanaka; S Momohara
Journal:  Ann Rheum Dis       Date:  2009-03-30       Impact factor: 19.103

8.  Association of common polymorphisms in known susceptibility genes with rheumatoid arthritis in a Slovak population using osteoarthritis patients as controls.

Authors:  Klaus Stark; Jozef Rovenský; Stanislava Blazicková; Hans Grosse-Wilde; Stanislav Ferencik; Christian Hengstenberg; Rainer H Straub
Journal:  Arthritis Res Ther       Date:  2009-05-15       Impact factor: 5.156

Review 9.  Epidemiology and genetics of rheumatoid arthritis.

Authors:  Alan J Silman; Jacqueline E Pearson
Journal:  Arthritis Res       Date:  2002-05-09

10.  Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility.

Authors:  Anne Barton; Wendy Thomson; Xiayi Ke; Steve Eyre; Anne Hinks; John Bowes; Laura Gibbons; Darren Plant; Anthony G Wilson; Ioanna Marinou; Ann Morgan; Paul Emery; Sophia Steer; Lynne Hocking; David M Reid; Paul Wordsworth; Pille Harrison; Jane Worthington
Journal:  Hum Mol Genet       Date:  2008-04-22       Impact factor: 6.150

View more
  4 in total

1.  Tespa1 is associated with susceptibility but not severity of rheumatoid arthritis in the Zhejiang Han population in China.

Authors:  Yunliang Yao; Hui Zhang; Shengwen Shao; Ge Cui; Ting Zhang; Hui Sun
Journal:  Clin Rheumatol       Date:  2015-03-04       Impact factor: 2.980

2.  CD40/TRAF1 decreases synovial cell apoptosis in patients with rheumatoid arthritis through JNK/NF-κB pathway.

Authors:  Tao Cheng; Jian Wu; Yaozeng Xu; Cuiping Liu; Huayong Zhang; Mingjun Wang
Journal:  J Bone Miner Metab       Date:  2022-08-12       Impact factor: 2.976

Review 3.  Management of Rheumatoid Arthritis: An Overview.

Authors:  Andrei-Flavius Radu; Simona Gabriela Bungau
Journal:  Cells       Date:  2021-10-23       Impact factor: 6.600

4.  Association of Complement C5 Gene Polymorphisms with Proliferative Diabetic Retinopathy of Type 2 Diabetes in a Chinese Han Population.

Authors:  Dengfeng Xu; Hong Yi; Shizhi Yu; Xiaosong Li; Yanbin Qiao; Weiwei Deng
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.